Page 3,911«..1020..3,9103,9113,9123,913..3,9203,930..»

Does intravenous transplantation of BMSCs promote neural regeneration after TBI?

Posted: Published on July 17th, 2014

PUBLIC RELEASE DATE: 15-Jul-2014 Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research The brain has a low renewable capacity for self-repair and generation of new functional neurons in the treatment of trauma, inflammation and cerebral diseases. Cytotherapy is one option to regenerate central nervous system that aim at replacing the functional depleted cells due to traumatic brain injury (TBI). Bone marrow mesenchymal stem cells (BMSCs) are also considered a candidate for cytotherapy because they can differentiate into neurons/nerve cells, pass across blood-brain barrier, migrate into the injured region, secrete neurotrophic factor, and provide microenvironment for neural regeneration. Prof. Mohammad Ali Khalili, Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Iran and his team administered TBI rats 3106 BMSCs via the tail vein and found that the BMSCs transplanted via the tail vein promoted nerve cell regeneration in injured cerebral cortex, which supplement the lost nerve cells. Related results were published in Neural Regeneration Research (Vol. 9, No. 9, 2014). Article: " Intravenous transplantation of bone marrow mesenchymal stem cells promotes neural regeneration after traumatic brain injury" by Fatemeh Anbari1, Mohammad Ali Khalili1, Ahmad Reza Bahrami2, Arezoo Khoradmehr1, Fatemeh Sadeghian1, Farzaneh Fesahat1, Ali Nabi1 (1 Research and … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Does intravenous transplantation of BMSCs promote neural regeneration after TBI?

Forty Per Cent of Female Prisoners Enter Correctional System with a Traumatic Brain Injury

Posted: Published on July 17th, 2014

Contact Information Available for logged-in reporters only Newswise TORONTO, July 17, 2014 A study published today found that almost 40 per cent of Ontario female prisoners have a history of traumatic brain injury (TBI). Unlike the men participating in the study, half of these women sustained a TBI before committing their first crime. The study, led by Dr. Angela Colantonio, senior scientist, Toronto Rehabilitation Institute, was based on a survey of men and women in Ontario correctional facilities. Published in the Journal of Correctional Health Care, it is the first Canadian study of its kind. Typically caused by a blow to the head, TBI is a leading cause of death and disability worldwide. It kills 11,000 Canadians every year. TBI is commonly caused by falls, motor vehicle collisions,physical assault or sports injuries. We observed a striking gender difference. Female inmates with a TBI, compared to males, were much more likely to have suffered physical or sexual abuse as children, said Colantonio, Canadian Institutes of Health Research (CIHR) Research Chair in Gender, Work, and Health, University of Toronto. Our research suggests the need to screen offenders and others with a history of abuse for TBI. Dr. Colantonio highlights the need to … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Forty Per Cent of Female Prisoners Enter Correctional System with a Traumatic Brain Injury

Diabetes stem cell therapy readied | UTSanDiego.com

Posted: Published on July 17th, 2014

Paul Laikind, CEO of ViaCyte, which is making a treatment for diabetes from human embryonic stem cells. In an historic announcement for the stem cell field, San Diego's ViaCyte said Thursday it has applied to start human clinical trials of its treatment for Type 1 diabetes. ViaCyte grows replacement insulin-producing cells from human embryonic stem cells. The cells are packaged while maturing in a semi-permeable device and implanted. In animal trials, the cells produce insulin, relieving diabetes. Now the company proposes to take what could be a cure for diabetes into people. ViaCyte has asked to begin a Phase 1/2 clinical trial, which would assess both safety and efficacy of its product. ViaCyte is targeting Type 1 diabetes, in which the insulin-producing cells are destroyed. Patients require multiple injections of insulin daily to survive. The announcement is good news for California's stem cell agency, the California Institute for Regenerative Medicine. The agency has awarded nearly $39 million to ViaCyte to ready its device for human use. Paul Laikind, ViaCytes chief executive, said if all goes smoothly, the first patients will be treated in August or September. Based on animal studies, it will take a few months to see results, and … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Diabetes stem cell therapy readied | UTSanDiego.com

Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis

Posted: Published on July 17th, 2014

We expect the results of this study to be highly informative and determine the therapeutic utility and differentiating features of ALKS 8700, said Dr. Elliot Ehrich, Chief Medical Officer of Alkermes. ALKS 8700 leverages Alkermes expertise in prodrug chemistry and oral controlled-release formulations to offer potential differentiated tolerability and dosing for patients with MS. This phase 1 study will investigate the pharmacokinetics and pharmacodynamics of multiple formulations and doses of ALKS 8700, and is designed to determine those suitable to progress into advanced clinical testing. The initiation of the phase 1 study follows Alkermes filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), and the issuance of a composition of matter patent for ALKS 8700 from the United States Patent and Trademark Office (USPTO) in March 2014, which is expected to provide patent protection into 2033. About ALKS 8700 ALKS 8700 is an oral, novel and proprietary monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis (MS). With properties designed to enable improved flexibility in the development of extended-release formulations, ALKS 8700 is designed to rapidly and efficiently convert to MMF in the body and to offer differentiated features as … Continue reading →

Posted in MS Treatment | Comments Off on Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis

Stem Cell Treatment Grows Nose on Woman's Spine – Video

Posted: Published on July 17th, 2014

Stem Cell Treatment Grows Nose on Woman's Spine Check out our Website! http://www.covertchronicle.com In a stem cell treatment to cure a woman's paralysis, the woman grew a nose like growth on her spine ... By: The Covert Chronicle … Continue reading →

Comments Off on Stem Cell Treatment Grows Nose on Woman's Spine – Video

PCP questions use of DAP funds in stem cell research

Posted: Published on July 17th, 2014

NewsLife: PCP pushes for more studies on stem cell therapy NewsLife - PCP pushes for more studies on stem cell therapy (Reported By: Dina Paguibitan) - [July 30, 2013] For more news, visit: http://www.ptvnews.ph Download our mobile App. in your Android phones to read daily news updates https://www.dropbox.com/s/qz9q1b2xu8pomoo/PTV_News_Android_03-20-2013.apk Subscribe to our youtube account: http://www.youtube.com/ptvphilippines Like our facebook page: PTV: http://facebook.com/PTVph NEWS@1: http://facebook.com/PTVnewsat1 NEWS@6: http://facebook.com/PTVnewsat6 NEWSLIFE: http://facebook.com/PTVnewslife PTV SPORTS: http://facebook.com/PTV4SPORTS Follow us at Twitter: http://twitter.com/PTVph Follow our livestream at http://ptvnews.ph/index.php/livestreammenu Ustream: http://www.ustream.tv/channel/ptv-livestream Watch us, every Monday to Friday Balitaan - 5:30 am - 7:00 am Good Morning Boss - 7:00 am - 9:00 am News@1 - 1:00 pm - 2:30 pm PTV Sports - 5:00 pm - 6:00 pm News@6 - 6:00 pm - 7:00 pm NewsLife - 9:15 pm - 10:30 pm Saturday: News@1 The Week That Was - 1:00 pm - 2:00 pm PTV Weekend News - 6:00 pm - 7:00 pm Sunday: News@1 Junior Edition - 1:00 pm - 2:00 pm PTV Weekend News - 6:00 pm - 7:00 pm The Rundown Live #276 Open Lines (Prisoner Exchange Psyop,Freemasons,Stem cells) (6/5/14) On this Thursday edition of The Rundown Live, Kristan and I go over the sponsors, and the … Continue reading →

Comments Off on PCP questions use of DAP funds in stem cell research

Lung Center defends DAP-funded stem cell program

Posted: Published on July 17th, 2014

PCP: Stem cell therapy untested, expensive, and experimental MANILA - The Lung Center of the Philippines (LCP) defended the P70 million it received as funding from the Disbursement Acceleration Program for a stem cell research project. LCP Executive Director Jose Luis J. Danguilan admitted receiving P105 million in total allocations from the DAP, which he said was spent wisely. He said P35 million was spent for the LCP's pediatric unit while the rest went to stem cell research. The stem cell research program was listed as the 15th item in the Department of Budget and Management list. It was named as the LCPs Bio-Regenerative Technology Program. The project intends to "fund the Bio-Regenerative Program aimed at harnessing stem cell research and technology to reconstruct new healthy cells, replacing cancer or dead cells." Danguilan said the equipment bought for both the stem cell and pediatric unit programs have other uses. "To spend the money wisely, it was decided that pieces of equipment needed for the Bioregenerative Program and the Pediatric Unit could also be used by the Department of Pathology and Laboratory, the Department of Thoracic Surgery and Surgery, the Department of Pulmonary Medicine and the Department of Radiology," he said. … Continue reading →

Comments Off on Lung Center defends DAP-funded stem cell program

2014 07 16 Embryonic Stem Cell Research – Video

Posted: Published on July 17th, 2014

2014 07 16 Embryonic Stem Cell Research Lawrence Goldstein, University of California, San Diego. By: Lynn Marquis … Continue reading →

Posted in Stem Cell Research | Comments Off on 2014 07 16 Embryonic Stem Cell Research – Video

Gene Profiling Technique to Accelerate Stem Cell Therapies for Eye Diseases

Posted: Published on July 17th, 2014

Contact Information Available for logged-in reporters only Newswise Researchers at the National Institutes of Health have developed a technique that will speed up the production of stem-cell derived tissues. The method simultaneously measures the expression of multiple genes, allowing scientists to quickly characterize cells according to their function and stage of development. The technique will help the researchers in their efforts to use patients skin cells to regenerate retinal pigment epithelium (RPE)a tissue in the back of the eye that is affected in several blinding eye diseases. It will also help the scientists search for drugs for personalized treatments. Progress in stem cell-based therapies has been limited by our capacity to authenticate cells and tissues, said Kapil Bharti, Ph.D., a Stadtman Investigator in the Unit on Ocular and Stem Cell Translational Research at the National Eye Institute (NEI), a part of NIH. This assay expands that capacity and streamlines the process. The assay was described in a recent issue of Stem Cells Translational Medicine. The RPE is a single layer of cells that lies adjacent to the retina, where the light-sensitive photoreceptors commonly called rods and cones are located. The RPE supports photoreceptor function. Several diseases cause the RPE to … Continue reading →

Posted in Stem Cell Research | Comments Off on Gene Profiling Technique to Accelerate Stem Cell Therapies for Eye Diseases

Entest BioMedical Inc. Recruits Salk Institute Researcher to Lead Cancer Stem Cell Program for Treating Feline …

Posted: Published on July 17th, 2014

Dr. Christine Ichim to assist in the development of the Company's canine immunotherapy for the treatment of cancer Dr. Ichim has done research on cancer stem cells for more than 14 years Entest BioMedical Inc. (PINKSHEETS: ENTB) announced today that Dr. Christine Ichim has joined the Company as Its Director of Research.Dr. Ichim was previously with the Salk Institute where she conducted research in the areas of cancer and stem cell division, cell senescence and aging. While at the University of Toronto, Dr. Ichim began developing research for the treatment of feline leukemia.Dr. Ichim has published her research in peer reviewed journals on immunological therapies for treating cancer.David Koos, Chairman & CEO of Entest BioMedical Inc. noted, "Dr. Ichim has a unique approach to treating leukemia and cancer.She is focused on cell senescence of cancer stem cells.This approach involves forcing cells that would normally become cancerous into a state of maturation where they no longer have the capacity to grow.Cancer cells typically have the ability to expand leading to life threatening conditions such as lung cancer.In this cell senescence approach, these cancer cells are no longer capable of expansion, thus rendering these cells harmless." Dr. Ichim stated, "I am extremely … Continue reading →

Posted in Stem Cell Research | Comments Off on Entest BioMedical Inc. Recruits Salk Institute Researcher to Lead Cancer Stem Cell Program for Treating Feline …

Page 3,911«..1020..3,9103,9113,9123,913..3,9203,930..»